Physician Connectivity: Electronic Prescribing by Strongin, Robin J.
No. 752
ISSUE BRIEF
Physician Connectivity:
Electronic Prescribing
Wednesday, February 23, 2000
Washington, DC
A discussion and demonstration featuring
Jean Paul Gagnon, Ph.D.
Director, Health Policy
Aventis Pharmaceuticals
David J. Gibson, M.D.
President
RxPhysician.com, Inc.
Helene Levens-Lipton, Ph.D.
Professor
Schools of Pharmacy and Medicine
University of California, San Francisco
Harold M. Koenig, M.D.
Surgeon General (retired)
U.S. Navy
With comments from a representative of the pharmacy industry
 2
 
Analyst/Writer: 
Robin J. Strongin
National Health Policy Forum
2021 K Street, NW, Suite 800
Washington, DC 20052
202/872-1390
202/862-9837 (fax)
nhpf@gwu.edu (e-mail)
www.nhpf.org (Web site)
Judith Miller Jones, Director
Karen Matherlee, Co-Director
Judith D. Moore, Co-Director
Michele Black, Publications Director
NHPF is a nonpartisan education and information
exchange for federal health policymakers.
ISSUE BRIEF/No. 752
Physician Connectivity
Physician connectivity—the electronic linking of
physicians with online resources such as clinical
databases and sophisticated formulary systems—is
allowing growing numbers of physicians to prescribe
online via a handheld computer complete with formu-
lary information as well as patient data and drug infor-
mation. Advocates of this technology point out that it
will yield fewer medication errors as well as increased
formulary compliance. Others, however, are not as
enthusiastic, citing general concerns about online
prescribing and purchasing.
On-line pharmacies are not only reshaping the way
pharmaceuticals are prescribed, dispensed, and distrib-
uted, but are also having a profound effect on the
parties involved: patients, doctors, pharmacists, bricks-
and-mortar drugstores, pharmacy benefit managers, and
entrepreneurs. As is the case in all sectors of the digital
economy, prescribing in cyberspace poses challenging
policy questions. As regulators tread gingerly, balanc-
ing First Amendment rights with consumer protection
and weighing ethical and safety issues against patient
empowerment and convenience, questions of jurisdic-
tion and responsibility have become entangled, result-
ing in regulatory limbo.
Many different types of prescriptions are written,
representing several distinctions which need to be
individually assessed in determining appropriate regula-
tory policy. The American Medical Association (AMA)
articulated these in its June 23, 1999, resolution oppos-
ing Internet prescribing. As reported in the July 19,
1999, issue of Millin’s Health Fraud Monitor, back-
ground materials prepared for the AMA’s House of
Delegates carefully distinguished between
legitimate telemedicine as opposed to mail order
pharmacy with a little electronic form perused by a
physician to give it legitimacy. There also were
distinctions for physicians ordering refills for patients
and physicians taking action over the Internet when
the physicians know the patients and have their
medical records available when prescribing. Simply
transmitting prescriptions to pharmacies via the
Internet was also distinguished.1
Not surprisingly, Wall Street has also taken an
interest in these online companies, and their relationship
to pharmaceutical prices, company margins, pharma-
ceutical benefit trends, and managed care profitability.
A new player has emerged to challenge the dominant
position enjoyed by the community-based pharmacy.
Online .com drug stores are healthcare destinations
for commerce and content. . . . The market is still
sorting out how to value these companies. For exam-
ple, companies like Drugstore.com trade at 398 times
trailing revenue, while a real estate–based Walgreen
trades at 1.4 times revenue. It is clear that, in the long
term, these virtual companies will be valued upon
their contractual relationships. It is also clear that
without front-end electronic connectivity to the
prescribing physician (emphasis added), the .com
pharmacies cannot deliver their promised increased
efficiencies to the marketplace.2
This Forum session will focus on physician connec-
tivity within the broader milieu of online prescribing.
Specifically, discussions will highlight the use of
information technology in managing pharmacy risk. To
show how the actual process works, one of the speakers
will demonstrate the use of electronic handheld wireless
technology. The audience will also learn how physician
connectivity is being used in the military. In addition,
speakers will address issues of e-commerce as well as
its intended and unintended consequences and its effect
on various stakeholders as traditional relationships are
redefined.
PRESCRIBING ONLINE
“Physicians should never again write a prescription.
Given the explosion of scientific information and
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advances in computer technology, prescribing medica-
tions on a blank piece of paper will soon seem as
antiquated as ordering tinctures of botanicals in Latin.”3
Gordon Schiff and Donald Rucker used the above
quote to open an April 1998 article in the Journal of the
American Medical Association extolling the virtues of
computerized prescribing. The authors wrote about the
positive impact computerized prescribing could have on
 Drug selection.
 Patient role in pharmacotherapy risk-benefit deci-
sion making.
 Screening for interactions (drug-drug, drug-labora-
tory, drug-disease).
 Linkages between laboratory and pharmacy.
 Dosing calculations and scheduling.
 Coordination between team members, particularly
concerning patient education.
 Monitoring and documenting adverse effects.
 Postmarketing surveillance of therapy outcomes.
The authors conceded, however, that “development of
this tool has been impeded by a number of conceptual,
implementation, and policy barriers.” The almost two
years since their article was published have seen great
advances in technology and the use of the Internet.
Computerized prescribing, where the physician enters
orders into pharmacy computers is evolving into today’s
more ergonomically acceptable handheld wireless
electronic prescription pad.
While some experts are concerned about the poten-
tial marketing and commercial exploitation of online
prescribing, advocates cheer its potential to improve the
quality of health care, decrease costs, manage risk
better, and increase efficiency.
Improving Quality and Enhancing
Efficiency
The Institute of Medicine’s (IOM’s) Committee on
Quality of Health Care in America released its report on
medical errors and patient safety on November 29,
1999. The report, which emphasized the widespread
nature of medical errors, including medication errors
and adverse drug reactions, stated that “having physi-
cians enter and transmit medication orders online
(computerized physician order entry) is a powerful
method of preventing medication errors due to misrep-
resentation of hand-written orders.” In addition to
eliminating errors stemming from illegible handwriting
on paper prescriptions, physician connectivity products
can supply the prescribing physician with several key
pieces of patient-specific data, including the patient’s
history and drug interaction warnings, enabling doctors
to closely monitor compliance and dosing regimens.
Advocates of physician connectivity also point to the
greater efficiencies such online information can provide
physicians and pharmacists. For example:
Reliance on the telephone to conduct health care
transactions is part of the inefficiency estimated to
cost the industry as much as $280 billion a year. In
round numbers, of the 30 billion health care transac-
tions per year, more than 90 percent are conducted by
phone, fax, or mail. At the moment, prescription
writing takes up an incredible amount of time. A
typical primary care doctor writes as many as 30
prescriptions daily and handles an equal number of
renewals. Renewals, usually triggered by a call from
the pharmacist, are particularly time-consuming. After
the patient’s chart is pulled, at a cost of $5 to $7, the
doctor must review the prescription, consider new
medical conditions that may have arisen, check the
patient’s formulary and drug history, and screen for
potential adverse reactions. A nurse then calls the
pharmacy back. Studies of doctors’ offices by Merck-
Medco found that nurses on average spend 80 percent
of their time handling prescriptions. For doctors, the
average is 30 minutes. More than half of the clinical
calls to doctors concern pharmacy issues.4
Physician connectivity would cut the time spent on
these issues dramatically. And, by enabling physicians
to send prescriptions directly to the retail pharmacy or
the mail order facility, physician connectivity promises
to further improve quality and enhance efficiency.
Decreasing Costs and Managing Risk
The improved efficiencies to doctors and pharma-
cists and  throughout the entire drug distribution system
is likely to lead to a restructuring in the marketplace. It
will be some time before all these interrelated factors
“shake out” but advocates of physician connectivity
predict these system efficiencies will translate into
overall cost savings, along with reductions in the
number of liability suits as quality improves and medi-
cation errors are reduced.
American consumers spend over $100 billion a year
on prescription medications. As more practice groups go
at risk, managing drug costs will be critical for their
survival. At the December 1999 National Congress on
the Future of Pharmaceuticals in Medical Care, David J.
Gibson, M.D., president of RxPhysician.com, indicated
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that practice groups making mistakes on their per-
member-per-month contracted budgets are financially
doomed and will fail. Also important is getting the trend
line right. According to Gibson, “a group cannot man-
age risk without a point-of-decision-making information
system,” that is, physician connectivity. At its core,
physician connectivity is a variation on the online
prescribing theme.
REGULATORY RESPONSIBILITY
HERE AND ABROAD
As traditional pharmacy “morphs” into online
pharmacy, the existing regulatory apparatus is ill-
equipped to deal with the complex emerging issues that
cross state, national, and international boundaries. It is
this issue that concerns many experts.
Domestic Sites
In the United States, non-over-the-counter medica-
tions require a prescription written by a physician. The
medication must be approved by the Food and Drug
Administration (FDA), the physician must be licensed
by a state medical board, and the pharmacy and its
pharmacists dispensing the medication must be licensed
by state pharmaceutical boards. Online pharmacies have
distorted this process. For example, in most states, a
physician’s prescribing of medications for patients
outside the state where the physician is licensed (which
often is the case with online pharmacies) constitutes the
unlicensed practice of medicine.
In some cases, physicians employed by Internet sites
(cyberdoctors) write prescriptions for “patients” they have
never met or examined, a practice the American Medical
Association has proclaimed unethical—although, as the
AMA points out, the practice is not illegal. Not all online
pharmacies employ cyberdocs or violate licensing laws,
however. Sites such as CVS.com (which purchased
Soma.com) and others do not use cyberdocs; rather,
prescriptions are verified by patients’ doctors over the
telephone. Also, many sites are or are in the process of
becoming licensed in every state in which they ship.
Still, the number of online pharmacy sites is growing
and many are arguably on shaky ground when it comes
to sound safety, ethical, and legal practices. A recent
court case, Missouri v. Stallknecht, highlights some of
these concerns. In this case, a Missouri judge issued an
injunction against the online Texas-based pharmacy,
Pillbox.com, owned by Bill Stallknecht, blocking the
site’s unlawful sale of prescription-only drugs to
Missourians over the Internet. Missouri Attorney
General Jeremiah “Jay” Nixon alleged that “the defen-
dants violated state medical and merchandising laws by
selling prescription drugs to consumers without a
license and on the basis of information provided solely
in on-line consultations.”5 Illinois and Kansas have filed
similar lawsuits.
Federal Authority
States are not alone in their efforts to combat un-
sound practices. The Federal Trade Commission is
concerned with consumer protection, rooting out fraud
and misinformation as well as shouldering responsibil-
ity for the advertising of nonprescription drug products.
The FDA oversees drug quality and the advertising of
prescription drugs, while the Drug Enforcement Admin-
istration regulates controlled substances. The Depart-
ment of Justice enforces civil consumer protection
statutes as well as criminal provisions. Lastly, the U.S.
Customs Service and the U.S. Postal Service enforce
regulations and laws governing the importation and
domestic mailing of pharmaceutical products.
As a result of congressional prodding, these agencies
are in the process of sorting out which agency should take
the lead responsibility for online prescribing activities. A
March 25, 1999, letter on the subject of Internet pharma-
ceutical sales, cosigned by Reps. Henry A. Waxman (D-
Calif.), John D. Dingell (D-Mich.), Ron Klink (D-Pa.),
and Sherrod Brown (D-Ohio), posed several questions to
the FDA as Commerce Committee Democrats pushed to
clarify which agency should take the lead. The following
were the six questions asked of the FDA:
 What agency or department (at either the state or
federal level) does FDA believe is the primary regula-
tor of Internet pharmacies? For this question, please
also identify and describe the roles of the other state/
federal agencies that may make up this structure.
 What specific activities or functions does FDA
believe it is responsible for with regard to regulating
Internet pharmacies? Please describe both the
precise activities now conducted by FDA, and the
number of full-time equivalents (FTEs) dedicated to
all identified efforts. Does FDA believe it has
enough resources to conduct the activities it pres-
ently feels are under its jurisdiction in this regard? If
not, what additional resources does FDA require?
 Does FDA believe that existing laws and regula-
tions, or the present state/federal regulatory structure
adequately regulate online pharmacy operations? If
not, what are the discrepancies, and what changes,
if any, does FDA believe must be made?
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 Please describe FDA’s knowledge regarding the
differences between existing online pharmacies. For
example, some reports suggest that most online
pharmacies only fill prescriptions. Other reports,
however, have suggested that some actually provide
for a doctor consultation (for example, a quick
questionnaire is submitted over the Internet, it is
reviewed, and then the prescription is approved and
sent directly to the patient without a doctor ever
seeing the patient). How prevalent is this latter
operation? Do any trends appear in comparing one
form of online pharmacy with another?
 What is FDA’s understanding of how these firms
deal with issues such as medical records, privacy/
protection, the selling of controlled substances, or
drug interactions? How serious are these issues and
what shortcomings, if any, do online pharmacies
have with regard to these issues? Does FDA have
any knowledge of how online pharmacies prevent
unqualified persons from receiving prescriptions?
Are online pharmacies more susceptible to fraud or
deception? If so, please explain how.
 Finally, what quality issues does FDA believe relate
to the methods used to ship online pharmaceutical
products, and does FDA believe it has jurisdiction in
this area?
The FDA responded to the questions of Waxman
and his colleagues with a letter dated May 7, 1999, and
signed by Melinda K. Plaisier, interim associate com-
missioner for legislative affairs, with copies sent to
Reps. Thomas J. Bliley Jr. (R-Va.), Michael Bilirakis
(R-Fla.), and Fred Upton (R-Mich.). (The FDA’s Web
site, at http://www.fda.gov, addresses many of the
issues raised in Waxman’s letter.)
Foreign Sites 
A June 18, 1999, FDA Week article, “House Panel
Asks Feds to Clarify Roles on Regulating Internet Rx,”
reported:
While the committee as a whole is looking into the
matter, congressional sources say a rift is developing
between Democrats and Republicans because the
Republicans are more protective of the states’ juris-
diction over pharmacies. But Democrats stress that the
problems posed by foreign sites are beyond the states’
ability to regulate on their own and need federal
intervention.
While all indications point to the eventual monitoring
of domestic drug Web sites for safe, ethical, and legal
practices, non-U.S. sites pose a monumental problem
from a regulatory and enforcement perspective. Robert
Pear reported in a January 9, 2000, New York Times
article that “the number of packages with prescription
drugs seized by the U.S. Customs Service totaled 9,725
in 1999, 4.5 times as many as in 1998.” Experts ac-
knowledge that this is only the tip of the iceberg. In
addition to violating import laws, many of the products
seized have been found to have been misbranded, non-
FDA approved, and of substandard quality. Successfully
remedying the safety, ethical and legal challenges will
require the cooperation of a wide range of authorities,
organizations, and regulatory agencies, as well as the
pharmaceutical and pharmacy industries themselves.
But the road ahead will not be smooth. Pear makes
the point in his January 9 article that
regulation of offshore Internet sites is tricky for the
Clinton administration because Vice President Al
Gore and other Democrats continually berate drug
companies for charging higher prices in the United
States than in other countries, and one of the main
reasons consumers buy online from foreign pharma-
cies is to get lower prices.
Others, however, take issue with the claim that prices of
pharmaceutical products purchased online are lower
and point to embarrassment and convenience as the
motivating forces for online purchasing:
Although many sites advertise lower prices to con-
sumers than otherwise available, Bloom and col-
leagues found that this was not the case. On average,
prices for Viagra and Propecia were about 10 percent
more expensive when they were obtained from a local
Web site than from a local pharmacy. Of course,
consumers may be willing to pay more for the conve-
nience of an online pharmacy.6
Nevertheless, the Clinton administration has moved
ahead with a plan to crack down on Internet pharmacy
irregularities by having the FDA require Web sites to
certify that they are in compliance with existing state
laws and to display a seal. The White House proposal
calls for $10 million for FDA to hire more personnel to
regulate both domestic and foreign sites that prescribe
and dispense drugs online.
In addition to the Clinton proposal, similar measures
are sprouting up in the private sector. In an effort to
assist consumers with determining “reputable” sites
(that is, sites that have licensed pharmacists), the
National Association of Boards of Pharmacy (NABP)
has established a voluntary certification program called
VIPPS—Verified Internet Pharmacy Practice Sites.
Receiving a VIPPS seal of approval requires on-site
inspection and compliance with 17 criteria, including
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documentation of licensure compliance in all jurisdic-
tions where the site conducts business. In a recent
development, the FDA is considering working with the
NABP to oversee pharmaceutical Web site inspections.
(Details, such as the retention of FDA oversight author-
ity and federal access to information, are still under
discussion.) In a similar vein, the Federation of State
Medical Boards is working with the AMA to develop a
model practice act that would delineate the minimum
steps necessary to generate a valid prescription, such as
taking a history, conducting a physical, and providing
a follow-up contact.
THE FORUM SESSION
A number of policy questions arise as experts
grapple with the complexities of online prescribing and
physician connectivity. Among them are the following:
 How will the traditional roles of pharmacist, physi-
cian, and patient evolve as a result of online pre-
scribing and physician connectivity?
 What impact will online prescribing and physician
connectivity have on future pharmacy benefit design?
 What role, if any, will online prescribing and physi-
cian connectivity play in research (that is, clinical
trial data gathering)?
 Who will have access to patient data?
 As physician connectivity takes hold, what effect
will it have on rebates? On drug prices?
 How will physician connectivity affect market share
of various drug products?
 Who bears the costs associated with physician
connectivity? Who realizes the savings (that is, from
improved physician compliance with formularies)?
 Are prescription drugs really less expensive when
purchased over the Internet, given shipping charges
and, in some cases, the lack of acceptance of pre-
scription drug insurance plans?
 How will the pharmaceutical distribution process
change as a digital infrastructure is incorporated into
the health care system?
 What, if any, is the future of group purchasing?
 What, if anything, can be done to protect consumers
against illegal offshore sites selling and distributing
prescription drugs in the United States?
 Who or what entity would be liable when someone
is injured as a result of receiving an incorrect or
impure online prescription or suffers some other
related injury?
 What are the minimum requirements for clinical
incorporation of a computer system?
This Forum session will begin with an overview of
e-commerce and an update on Internet pharmacies by
Jean Paul Gagnon, Ph.D., director of health policy for
Aventis Pharmaceuticals (the new life sciences com-
pany resulting from the merger of Hoechst Marion
Roussel and Rhone-Poulenc Rorer). David J. Gibson,
M.D., president of RxPhysician.com, will discuss the
use of information technology to manage pharmacy
risk. Dr. Gibson will provide a demonstration of the
cutting-edge technology being piloted in many physi-
cian practices today. Helene Levens-Lipton, Ph.D., a
professor at the Schools of Pharmacy and Medicine at
the University of California at San Francisco, will
address the issue of patient-provider relationships,
examining the intended and unintended consequences
of online prescribing. Physician connectivity is not a
new phenomenon in the military. Harold M. Koenig,
M.D., a retired surgeon general of the navy, will
highlight the lessons learned regarding the use of online
prescribing and physician connectivity in military
medicine. Wrapping up the session will be comments
from a representative of the pharmacy industry.
ENDNOTES
